{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T01:40:02Z","timestamp":1746495602537,"version":"3.40.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Health, Labor and Welfare, Japan"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.pbb.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T21:17:08Z","timestamp":1414790228000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model"],"prefix":"10.1016","volume":"127","author":[{"given":"Kiyoshi","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2014.10.009_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNF.0b013e3181d47849","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease","volume":"33","author":"Adamiak","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/jnnp.2008.154948","article-title":"Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36months","volume":"80","author":"Alvarez","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pbb.2014.10.009_bb0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-007-0929-2","article-title":"Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets","volume":"195","author":"Ando","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0025","doi-asserted-by":"crossref","first-page":"e46371","DOI":"10.1371\/journal.pone.0046371","article-title":"PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease","volume":"7","author":"Ando","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pbb.2014.10.009_bb0030","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/026119299502300614","article-title":"The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11","volume":"23","author":"Balls","year":"1995","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.pbb.2014.10.009_bb0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2014.10.009_bb0040","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1523\/JNEUROSCI.22-14-05817.2002","article-title":"Enhanced inhibition of synaptic transmission by dopamine in the nucleus accumbens during behavioral sensitization to cocaine","volume":"22","author":"Beurrier","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S031716710003849X","article-title":"Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients","volume":"23","author":"Blanchet","year":"1996","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0050","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0006-8993(95)00229-J","article-title":"Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex","volume":"680","author":"Calon","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2014.10.009_bb0060","first-page":"S70","article-title":"Molecular basis of levodopa-induced dyskinesias","volume":"47","author":"Calon","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0065","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/syn.20527","article-title":"Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat","volume":"62","author":"Carta","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2014.10.009_bb0070","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbr.2010.10.016","article-title":"Association between striatal accumulation of FosB\/DeltaFosB and long-term psychomotor sensitization to amphetamine in mice depends on the genetic background","volume":"217","author":"Conversi","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.10.009_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism\u2014chronic treatment with l-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pbb.2014.10.009_bb0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MOT.0b013e32834c2356","article-title":"Clinical translation of cell transplantation in the brain","volume":"16","author":"Dunnett","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.pbb.2014.10.009_bb0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-2006-944314","article-title":"Dyskinesia in Parkinson's disease\u2014major clinical features, aetiology, therapy","volume":"75","author":"Ellrichmann","year":"2007","journal-title":"Fortschr Neurol Psychiatr"},{"key":"10.1016\/j.pbb.2014.10.009_bb0095","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainresbull.2005.08.005","article-title":"Marmoset monkey models of Parkinson's disease: which model, when and why?","volume":"68","author":"Eslamboli","year":"2005","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pbb.2014.10.009_bb0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0404.1966.tb01188.x","article-title":"Treatment of Parkinson's syndrome with l-DOPA. A double blind study","volume":"42","author":"Fehling","year":"1966","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pbb.2014.10.009_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","article-title":"The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future","volume":"184","author":"Fox","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.pbb.2014.10.009_bb0110","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov Disord"},{"issue":"Suppl. 3","key":"10.1016\/j.pbb.2014.10.009_bb0115","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0120","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/mds.21440","article-title":"Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease","volume":"22","author":"Fuxe","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0125","first-page":"196028","article-title":"Metabotropic glutamate receptors for Parkinson's disease therapy","volume":"2013","author":"Gasparini","year":"2013","journal-title":"Park Dis"},{"key":"10.1016\/j.pbb.2014.10.009_bb0130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.2042-7158.1991.tb03188.x","article-title":"Comparison of sensitization to ambulation-increasing effects of cocaine and methamphetamine after repeated administration in mice","volume":"43","author":"Hirabayashi","year":"1991","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pbb.2014.10.009_bb0140","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1111\/j.1460-9568.2005.04169.x","article-title":"Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets","volume":"21","author":"Hurley","year":"2005","journal-title":"Eur J NeuroSci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0145","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2014.10.009_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl. 4","key":"10.1016\/j.pbb.2014.10.009_bb0155","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1353-8020(09)70829-6","article-title":"From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0160","first-page":"15","article-title":"Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved?","volume":"53","author":"Jones","year":"2007","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1742-1241.2011.02793.x","article-title":"Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease","volume":"65","author":"Kalinderi","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pbb.2014.10.009_bb0170","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1523\/JNEUROSCI.13-01-00266.1993","article-title":"Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals","volume":"13","author":"Kalivas","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0175","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1601-183X.2008.00392.x","article-title":"Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice","volume":"7","author":"Kelly","year":"2008","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.pbb.2014.10.009_bb0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pbb.2014.10.009_bb0185","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1523\/JNEUROSCI.14-09-05623.1994","article-title":"Amphetamine regulates gene expression in rat striatum via transcription factor CREB","volume":"14","author":"Konradi","year":"1994","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","article-title":"Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease","volume":"41","author":"Kostic","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0195","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00702-007-0727-3","article-title":"l-DOPA dose and the duration and severity of dyskinesia in primed MPTP-treated primates","volume":"114","author":"Kuoppamaki","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pbb.2014.10.009_bb0200","first-page":"49","article-title":"MPTP-induced parkinsonism in human and non-human primates\u2014clinical and experimental aspects","volume":"100","author":"Langston","year":"1984","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.pbb.2014.10.009_bb0205","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","article-title":"Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy","volume":"29","author":"Lesser","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S1092852912000752","article-title":"New insights into the mechanism of drug-induced dyskinesia","volume":"18","author":"Loonen","year":"2013","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pbb.2014.10.009_bb0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbr.2009.01.034","article-title":"Long-lasting sensitization of reward-directed behavior by amphetamine","volume":"201","author":"Mendez","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.10.009_bb0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/2013.jamaneurol.45","article-title":"History, applications, and mechanisms of deep brain stimulation","volume":"70","author":"Miocinovic","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-6147(93)90082-U","article-title":"Is l-DOPA an endogenous neurotransmitter?","volume":"14","author":"Misu","year":"1993","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0230","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp.34.6.668","article-title":"Analysis of l-DOPA induced dyskinesias in 51 patients with Parkinsonism","volume":"34","author":"Mones","year":"1971","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pbb.2014.10.009_bb0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson's disease","volume":"1","author":"Muller","year":"2012","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.pbb.2014.10.009_bb0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/WNF.0b013e31828f3385","article-title":"Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa\/carbidopa\/entacapone for treatment of levodopa-associated motor complications","volume":"36","author":"Muller","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0245","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0250","first-page":"323686","article-title":"Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia","volume":"2012","author":"Navailles","year":"2012","journal-title":"Park Dis"},{"key":"10.1016\/j.pbb.2014.10.009_bb0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1248\/bpb.b12-00929","article-title":"Therapeutic application of stem cell technology toward the treatment of Parkinson's disease","volume":"36","author":"Nishimura","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pbb.2014.10.009_bb0260","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FBP.0b013e32830cd7f5","article-title":"Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice","volume":"19","author":"Nordquist","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0265","first-page":"11","article-title":"Motor complications associated with chronic levodopa therapy in Parkinson's disease","volume":"39","author":"Obeso","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0270","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ana.410290516","article-title":"Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease","volume":"29","author":"Olanow","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0275","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0290","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic l-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0285","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002130050861","article-title":"Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated l-DOPA-primed common marmosets","volume":"142","author":"Pearce","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0280","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","article-title":"l-DOPA induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations","volume":"156","author":"Pearce","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2014.10.009_bb0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mds.1075","article-title":"Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate","volume":"16","author":"Petzinger","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0300","article-title":"Modeling Parkinson's disease in monkeys for translational studies, a critical analysis","author":"Potts","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","article-title":"The neural basis of drug craving: an incentive-sensitization theory of addiction","volume":"18","author":"Robinson","year":"1993","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.pbb.2014.10.009_bb0310","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets","volume":"546","author":"Rose","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/syn.20469","article-title":"Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of l-DOPA-induced dyskinesias in MPTP parkinsonian monkeys","volume":"62","author":"Samadi","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2014.10.009_bb0320","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0022-3565(25)30031-5","article-title":"Increased running response to morphine in morphine-pretreated mice","volume":"192","author":"Shuster","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.10.009_bb0325","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0330","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40263-013-0053-2","article-title":"Management of motor and non-motor symptoms in Parkinson's disease","volume":"27","author":"Sprenger","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2014.10.009_bb0335","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mds.10183","article-title":"The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys","volume":"17","author":"Tan","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.pbb.2014.10.009_bb0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0006-3223(01)01106-4","article-title":"Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, d-amphetamine and 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d)","volume":"50","author":"Taylor","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.10.009_bb0345","first-page":"267","article-title":"Update on deep brain stimulation for Parkinson's disease","volume":"56","author":"Terzic","year":"2012","journal-title":"J Neurosurg Sci"},{"key":"10.1016\/j.pbb.2014.10.009_bb0350","first-page":"7","article-title":"One to two year treatment of Parkinson's disease with levodopa","volume":"114","author":"Treciokas","year":"1971","journal-title":"Calif Med"},{"key":"10.1016\/j.pbb.2014.10.009_bb0355","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pbb.2014.10.009_bb0360","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00008877-199308000-00007","article-title":"Psychomotor-stimulant sensitization: a unitary phenomenon?","volume":"4","author":"Wise","year":"1993","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2014.10.009_bb0365","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1212\/WNL.52.4.763","article-title":"Loss of long-duration response to levodopa over time in PD: implications for wearing-off","volume":"52","author":"Zappia","year":"1999","journal-title":"Neurology"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T01:25:01Z","timestamp":1746494701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305714002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":73,"alternative-id":["S0091305714002925"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2014.10.009","relation":{},"ISSN":["0091-3057"],"issn-type":[{"type":"print","value":"0091-3057"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}